The drug is now approved for treating people with an LVEF of at least 40%, with or without chronic kidney disease.

Following priority review, the FDA approved Kerendia for the treatment of patients with heart failure with left ventricular ejection fraction (LVEF) ≥40%.

BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, announced today that Henry Ford Health in Detroit, ...

US FDA approves Bayer’s finerenone for new indication in patients with heart failure with left ventricular ejection fraction of ≥ 40%: Berlin Wednesday, July 16, 2025, 13:00 H ...

The approval was supported by data from the randomized, double-blind, placebo-controlled, event-driven phase 3 FINEARTS-HF study.

The FDA has broadened the approved use of finerenone (Kerendia) to include treatment for heart failure, according to an ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care ...

Bayer’s Kerendia (finerenone) has been approved by the US Food and Drug Administration (FDA) to treat heart failure (HF) patients with left ventricular ejection fraction (LVEF) of at least 40%.

An artificial intelligence model developed by Mayo Clinic and Ultromics accurately screens for cardiac amyloidosis using a ...

Patients with overweight or obesity and heart failure with preserved ejection fraction that have unintentional weight loss have worse outcomes.

CVRx (Nasdaq:CVRX) announced today that CMS proposed to keep its Barostim implant procedure within a certain payment class.

CVRx, Inc. (NASDAQ: CVRX) ('CVRx”), a commercial-stage medical device company, announced today that the Centers for Medicare ...